RU2017136047A - Composition for the treatment of Parkinson's disease - Google Patents

Composition for the treatment of Parkinson's disease Download PDF

Info

Publication number
RU2017136047A
RU2017136047A RU2017136047A RU2017136047A RU2017136047A RU 2017136047 A RU2017136047 A RU 2017136047A RU 2017136047 A RU2017136047 A RU 2017136047A RU 2017136047 A RU2017136047 A RU 2017136047A RU 2017136047 A RU2017136047 A RU 2017136047A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
dosage form
composition described
finished
cryoprotectant
Prior art date
Application number
RU2017136047A
Other languages
Russian (ru)
Other versions
RU2697411C2 (en
RU2017136047A3 (en
Inventor
Наталья Валерьевна Пятигорская
Галина Эдуардовна Бркич
Алексей Никитич Павлов
Геворкбек Гайкович Барсегян
Андрей Алексеевич Свистунов
Вадим Владимирович Тарасов
Людмила Анатольевна Павлова
Ирина Григорьевна Кондрашева
Original Assignee
федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) filed Critical федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет)
Priority to RU2017136047A priority Critical patent/RU2697411C2/en
Publication of RU2017136047A publication Critical patent/RU2017136047A/en
Publication of RU2017136047A3 publication Critical patent/RU2017136047A3/ru
Application granted granted Critical
Publication of RU2697411C2 publication Critical patent/RU2697411C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (5)

1. Фармацевтическая композиция, представляющая собой лекарственную форму в виде капель назальных, включающая в качестве действующего вещества аминокислоту (3,4-дигидрокси-L-фенилаланин, леводопа, L-ДОФА), распределенную в полимерной матрице на основе биодеградируемого сополимера молочной/гликолевой кислот (полилактидгликолид, PLGA 50/50), с включением в процессе производства субстанции поливинилового спирта (ПВС), как стабилизатора эмульсии и криопротектора - D-маннита, а также вспомогательных веществ, введенных на этапе производства готовой лекарственной формы: масла оливкового, твин-80.1. Pharmaceutical composition, which is a dosage form in the form of nasal drops, including as an active substance an amino acid (3,4-dihydroxy-L-phenylalanine, levodopa, L-DOPA), distributed in a polymeric matrix based on a biodegradable lactic / glycolic acid copolymer (polylactide glycolide, PLGA 50/50), with the inclusion in the production process of the substance of polyvinyl alcohol (PVA), as a stabilizer of the emulsion and cryoprotectant - D-mannitol, as well as auxiliary substances introduced during the production of the finished l dosage form: olive oil, twin-80. 2. Фармацевтическая композиция, охарактеризованная по п. 1, отличающаяся тем, что она содержит в каждом флаконе (масс./об.%)2. The pharmaceutical composition described in accordance with claim 1, characterized in that it contains in each vial (w / v%)
Figure 00000001
Figure 00000001
 3. Способ приготовления фармацевтической композиции, охарактеризованной в любом из пп. 1-2, включающий изготовление суспензии в растворе полимера PLGA 50/50; добавление криопротектора на этапе производства; проведение лиофильной сушки; добавление вспомогательных веществ для получения готовой лекарственной формы, розлив раствора во флаконы; укупорку флаконов крышкой с винтовой резьбой с маслостойкой пипеткой с готовой продукцией.3. The method of preparation of the pharmaceutical composition described in any of paragraphs. 1-2, including the manufacture of suspensions in a solution of the polymer PLGA 50/50; addition of cryoprotectant at the production stage; freeze drying; adding auxiliary substances to obtain the finished dosage form, pouring the solution into vials; closure of bottles with screw cap with oil resistant pipette with finished products. 4. Применение фармацевтической композиции, охарактеризованной в любом из пп. 1-2, для лечения нейродегенеративных заболеваний, в частности, болезни Паркинсона.4. The use of the pharmaceutical composition described in any of paragraphs. 1-2, for the treatment of neurodegenerative diseases, in particular, Parkinson's disease.
RU2017136047A 2017-10-11 2017-10-11 Composition for treating parkinson's disease RU2697411C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2017136047A RU2697411C2 (en) 2017-10-11 2017-10-11 Composition for treating parkinson's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2017136047A RU2697411C2 (en) 2017-10-11 2017-10-11 Composition for treating parkinson's disease

Publications (3)

Publication Number Publication Date
RU2017136047A true RU2017136047A (en) 2019-04-11
RU2017136047A3 RU2017136047A3 (en) 2019-04-11
RU2697411C2 RU2697411C2 (en) 2019-08-14

Family

ID=66167982

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017136047A RU2697411C2 (en) 2017-10-11 2017-10-11 Composition for treating parkinson's disease

Country Status (1)

Country Link
RU (1) RU2697411C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115707462A (en) * 2021-08-19 2023-02-21 沈阳药科大学 Levodopa composition for improving brain targeting and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
ATE428371T1 (en) * 1998-07-17 2009-05-15 Pacira Pharmaceuticals Inc BIODEGRADABLE ARRANGEMENTS FOR THE CONTROLLED RELEASE OF ENCLOSED SUBSTANCES
US6376545B1 (en) * 1998-11-10 2002-04-23 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing L-DOPA ethyl ester
WO2003041646A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
JP2008534563A (en) * 2005-03-28 2008-08-28 オレクソ・アクチエボラゲット New pharmaceutical compositions useful for the treatment of Parkinson's disease
RU2545734C1 (en) * 2014-01-31 2015-04-10 Открытое акционерное общество "Всероссийский Научный Центр Молекулярной Диагностики и Лечения" (ОАО "ВНЦМДЛ) Drug preparation for parkinson disease

Also Published As

Publication number Publication date
RU2697411C2 (en) 2019-08-14
RU2017136047A3 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
AU2020220142B2 (en) Low molecular weight silk compositions and stabilizing silk compostions
US20160263228A1 (en) Low molecular weight silk compositions and stabilizing silk compositions
CL2017001115A1 (en) Stable formulation of protein in solution that contains a high concentration of an anti-vegf antibody.
EA201892173A1 (en) PHARMACEUTICAL COMPOSITION OF PALBOCYCLIBE AND METHOD FOR PRODUCING IT
Bruggeman et al. Temporally controlled growth factor delivery from a self-assembling peptide hydrogel and electrospun nanofibre composite scaffold
BR112015023168A8 (en) crystalline diketopiperazine composition, methods of producing diketopiperiperine particles, producing a composition and treating and using a crystalline diketopiperazine composition
EP3763703A3 (en) Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof
EA201992570A1 (en) COMPOSITIONS BASED ON HUMAN ANTIBODIES TO RANKL, AND ALSO WAYS OF THEIR APPLICATION
Ryu et al. Dry tablet formulation of PLGA nanoparticles with a preocular applicator for topical drug delivery to the eye
CY1120891T1 (en) PHARMACEUTICAL COMPOSITION OF SLOW RELEASE MADE MADE OF MICROPARTICLES
Stephansen et al. Interactions between surfactants in solution and electrospun protein Fibers: Effects on release behavior and fiber properties
Amato et al. Local delivery and controlled release drugs systems: a new approach for the clinical treatment of periodontitis therapy
CA2926169A1 (en) Continuous release compositions made from hyaluronic acid, and therapeutic applications of same
CN107982239A (en) Hydrophobic drug crystal is the aspherical micro-capsule of albumen base and preparation method of template
RU2017136047A (en) Composition for the treatment of Parkinson's disease
EA201300487A1 (en) MODIFIED PEPTIDES WITH ANTI-VIRUS PROPERTIES AND METHOD OF OBTAINING THEM
ES2947659T3 (en) Processing method for biopolymers using solvent combinations
EA202092922A1 (en) PHARMACEUTICAL COMPOSITION WITH IMPROVED SOLUBILITY AND BIOLOGICAL AVAILABILITY
raja Kumar et al. Evaluation of Antifungal Activity of Sustained Release Microsponge Enriched Fluconazole Gel for Penile Candidiasis in Male Rats Int
EA201700521A2 (en) METHOD OF OBTAINING A NATIVE PROTECTION PROTECTIVE PROTEIN ACTION IN THE COMPOSITION OF POLYMERIC NANOSPHERE AND RECESSED MICROSPHERE FOR DELIVERY
EA043753B1 (en) BIOADHESIVE ANTIBACTERIAL AGENT, METHOD OF ITS MANUFACTURE (OPTIONS)
RU2649743C1 (en) Liquid dosage form containing drug substance placed in biodegradable polymers
CL2022002193A1 (en) Formulations of human anti-tslp antibodies and methods of treatment of an inflammatory disease
UA119632C2 (en) METHOD OF OBTAINING SOLID DISPERSIONS OF INSOLUBLE SUBSTANCES IN AQUATIC ENVIRONMENT
AR121329A1 (en) HUMAN ANTI-TSLP ANTIBODY FORMULATIONS AND METHODS OF TREATMENT OF AN INFLAMMATORY DISEASE